Alx Oncology Holdings Inc 8-K, filed Jun 11, 2026
Alx Oncology Holdings Inc (ALXO)
About this 8-K
Alx Oncology Holdings Inc filed this 8-K on June 11, 2026, reporting on events of June 10, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of matters to a vote of security holders.
ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of Two Class II Directors
Name of Director |
|
For |
|
|
Withheld |
|
|
Broker Non-Votes |
|
|||
Daniel Curran, M.D. |
|
|
100,933,233 |
|
|
|
57,798 |
|
|
|
18,313,833 |
|
Rekha Hemrajani |
|
|
82,732,430 |
|
|
|
18,258,601 |
|
|
|
18,313,833 |
|
Chris Takimoto, M.D., Ph.D., F.A.C.P. |
|
|
100,946,696 |
|
|
|
44,335 |
|
|
|
18,313,833 |
|
Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers
For |
|
|
Against |
|
|
Abstain |
|
|
Broker Non-Votes |
|
||||
|
84,540,061 |
|
|
|
13,497,711 |
|
|
|
2,953,259 |
|
|
|
18,313,833 |
|
The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.
Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm
For |
|
|
Against |
|
|
Abstain |
|
|||
|
119,293,775 |
|
|
|
1,797 |
|
|
|
9,292 |
|
The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ALX ONCOLOGY HOLDINGS INC. |
|
|
|
|
|
|
|
|
|
Date: June 11, 2026 |
|
By: |
/s/ Harish Shantharam |
|
|
|
Harish Shantharam |
|
|
|
Chief Financial Officer |